A move US regulators acknowledged as a departure from the norm in their processes – publishing guidance before a rule – likely helped HRA Pharma prepare its new drug application for an OTC daily oral contraceptive.
The Perrigo Company PLC business submitted to the Food and Drug Administration its switch NDA for 0